tbuckley/cabot-search huggingface dataset:
A phase IIa trial to assess the safety and efficacy of BL-8040 and pembrolizumab in patients with metastatic pancreatic adenocarcinoma (PDAC)
Authors: M. Hidalgo, R. Epelbaum, B.M. Wolpin, S.M. Stemmer, R. Geva, T. Golan, E. Borazanci, M. Borad, K.S. Pedersen, J.O. Park, R. Ramirez, A. Peled, T.M. Lustig, O. Bohana Kashtan, O. Rosenfeld, E. Sorani, K. Schlienger, A. Vainstein Haras, D.D. Von Hoff
Journal: Annals of Oncology (2018)
MA19.10 Impact of STK11/LKB1 Genomic Alterations on Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC
Authors: F. Skoulidis, Y. Elamin, V. Lam, J. Zhang, J. Lewis, W. Rinsurongkawong, J. Lee, J. Roth, S. Swisher, V. Papadimitrakopoulou, J. Heymach
Journal: Journal of Thoracic Oncology (2018)
MA26.10 CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC
Authors: L. Paz-Ares, D. Planchard, J.C. Yang, K. Lee, P. Garrido, K. Park, J. Kim, D.H. Lee, H. Mao, B. Chao, H. Yu
Journal: Journal of Thoracic Oncology (2018)
Breast cancer in Twitter: A real-world data exploratory study
Authors: R. Sanchez Bayona, L. Chang-Azancot, M.A. Alvarez de Mon, M. Llavero, M. Vallejo, I. Gardeazabal, D. Salas, P. Sala Elarre, I. Baraibar Argota, I. Eguren, M. Santisteban Eslava, L. Ceniceros, E. Castanon Alvarez
Journal: Annals of Oncology (2018)
Clinical efficacy of eribulin as first- or second-line treatment for patients with recurrent HER2-negative breast cancer: A phase II randomized study (JBCRG-19)
Authors: K.-I. Watanabe, K. Aogi, M. Kitada, T. Sangai, S. Ohtani, T. Aruga, H. Kawaguchi, T. Fujisawa, S. Maeda, T. Morimoto, S. Morita, N. Masuda, M. Toi, S. Ohno
Journal: Annals of Oncology (2018)
Cetuximab + platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE)
Authors: C. Le Tourneau, M. Ghiani, M.C. Cau, R. Depenni, G. Ronzino, P. Bonomo, V. Montesarchio, L. Leo, J. Schulten, D. Messinger, A. Sbrana, M.G. Ghi
Journal: Annals of Oncology (2018)
MA23.05 Post-Operative Radiation Improves Overall Survival in Patients with Node-Positive Non-Small Cell Lung Cancer Undergoing Sublobar Resections
Authors: K.F. Uy, R. Voland, J. Varlotto, M. Decamp, K. Mckie, D. Maddox, P. Rava, T. Fitzgerald, J. Toth, P. Oliveira, M. Reed, C. Belani, J. Baima, J. Zhang, W. Walsh, M. Patel, M. Rosen, L. Mcintosh, N. Rassaei, J. Flickinger
Journal: Journal of Thoracic Oncology (2018)
MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC
Authors: A. Levy, L. Hendriks, T. Berghmans, C. Faivre-Finn, M. Giaj Levra, N. Giaj-Levra, B. Hasan, N. Girard, L. Greillier, S. Lantuejoul, J. Edwards, M. O’Brien, M. Reck, B. Besse, S. Novello, A. Dingemans
Journal: Journal of Thoracic Oncology (2018)
Danish-like Regulations May Improve Postabortion Mental Health Risk
Authors: D. Paul Sullins, Donna Harrison
Journal: JAMA Psychiatry (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Effect of a community-based integrated nurturing care interventions on early childhood development in rural China: a quasi-experimental study
Authors: Suizan Zhou, Chunxia Zhao, Xiaona Huang, Zhiwen Li, Rongwei Ye, Huifeng Shi, Qi Zhao, Ye Zhou, Xuefeng Chen, Margo O'Sullivan, Ron Pouwels, Kathryn Martin, Jingxu Zhang, Xiaoli Wang, Robert W Scherpbier
Journal: The Lancet (2018)
P2.06-26 Ribonucleotide Reductase Subunit M1 but not M2 is Associated to Better PFS in Patients with Advanced Stage Mesothelioma
Authors: S. Muñiz-Hernández, L. Ramírez-Tirado, A. Maldonado, D. Hernandez-Cueto, G. Baay-Guzman, S. Huerta-Yepez, O. Arrieta
Journal: Journal of Thoracic Oncology (2018)
MA19.02 Prior Therapy and Increased Expression of PD-L1 in NSCLC Tumor Samples
Authors: A. Boothman, M. Scott, M. Ratcliffe, J. Whiteley, P. Dennis, C. Wadsworth, A. Sharpe, N. Rizvi, M. Garassino, J. Walker
Journal: Journal of Thoracic Oncology (2018)
P1.03-25 The Frequency and Prognosis of ATM Mutations in Chinese Non-Small-Cell Lung Cancer Patients
Authors: C. Han, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
P1.09-13 Detection of Actionable Mutations in Plasma cfDNA Samples From NSCLC Patients Using a Novel Amplicon-Based Firefly NGS Assay
Authors: J. Lou, L. Wang, L. Weng, X. Chen, M. Li, Q. Guo, W. Yu, Q. Meng, H. Wang, T. Wittkop, G.Q. Zhao, M. Fahem, S. Lin
Journal: Journal of Thoracic Oncology (2018)
Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial
Authors: R. Hui, A. Pearson, J. Cortes Castan, C. Campbell, C. Poirot, H.A. Azim, D. Fumagalli, M. Lambertini, F. Daly, A. Arahmani, J. Perez-Garcia, P.G. Aftimos, P. Bedard, L. Xuereb, S. Loibl, S. Loi, M.-J. Pierrat, N.C. Turner, F. André, G. Curigliano
Journal: Annals of Oncology (2018)
P1.01-102 Retrospective Analysis of Immune Checkpoint Inhibitors in Patients with EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort
Authors: T. Yamada, S. Shiotsu, K. Tanimura, T. Harada, Y. Kubota, T. Takeda, S. Watanabe, J. Uchino, K. Takayama
Journal: Journal of Thoracic Oncology (2018)
Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43
Authors: Alexandra M. Wennberg, Nirubol Tosakulwong, Timothy G. Lesnick, Melissa E. Murray, Jennifer L. Whitwell, Amanda M. Liesinger, Leonard Petrucelli, Bradley F. Boeve, Joseph E. Parisi, David S. Knopman, Ronald C. Petersen, Dennis W. Dickson, Keith A. Josephs
Journal: JAMA Neurology (2018)

Transactive response DNA-binding protein 43 (TDP-43) is associated with Alzheimer disease (AD), progressive hippocampal atrophy, and cognitive decline. The apolipoprotein E (APOE) ε4 allele is strongly associated with β-amyloid (Aβ) aggregation and risk of AD, but its association with TDP-43 is unknown.To determine whether the APOE ε4 allele is a risk factor for TDP-43.This cross-sectional, genetic-histologic study analyzed APOE genotype, TDP-43 status (positive vs negative), Aβ status (positive vs negative), and tau neurofibrillary tangle stage (B0, Braak stage 0; B1, Braak stages I-II; B2, Braak stages III-IV; B3, Braak stage ≥ V). We fit structural equation models to map the association between APOE and TDP-43, Aβ, and tau, accounting for age and hippocampal sclerosis. We identified 751 participants with an AD pathological spectrum diagnosis and completed Aβ, tau, and TDP-43 data who were enrolled in the Mayo Clinic Alzheimer Disease Research Center, Mayo Clinic Alzheimer Disease Patient Registry, or the population based Mayo Clinic Study of Aging and died between May 12, 1999, and December 31, 2015. However, 13 were excluded from the analyses because of missing APOE data, leaving a total of 738 participants.Transactive response DNA-binding protein 43 was the main outcome of interest. We hypothesized that the APOE ε4 allele would be significantly directly and indirectly associated with TDP-43.The 751 study participants were older (median age [interquartile range], 87 years [51-105 years]), 395 (54%) were women, and 324 (44%) were APOE ε4 carriers. The patients died between May 12, 1999, and December 31, 2015. Accounting for age, Aβ, and tau, APOE ε4 had a direct association with TDP-43 (estimate [SE], 0.31 (0.11); P = .01). The association was present among individuals with an intermediate to high likelihood of having AD (neurofibrillary tangle stage B2/B3; n = 604 [81.8%]; estimate [SE], 0.51 [0.11]; P < .001), with a similar trend for those with a low likelihood of having AD (B1; n = 134 [18.2%]; estimate [SE], 0.54 [0.32]; P = .10). We also found an indirect association of APOE ε4 with TDP-43 via Aβ and tau (estimate [SE], 0.34 [0.06]; P < .001), which was similar in magnitude to the direct association and an indirect association of APOE ε4 with hippocampal sclerosis via TDP-43 (estimate [SE], 0.65 [0.26]; P = .01).The study's findings, which mapped a system of risk factors and outcomes, showed that the APOE ε4 allele appears to be a risk factor for TDP-43 independently of Aβ in patients with AD.
P1.09-07 PD-L1 Protein Expression is a Predictor of Benefit from Adjuvant Chemotherapy in Resected Non-Small Cell Lung Carcinoma
Authors: N. Yanagawa, S. Shiono, M. Endo, None Suzuki, K. Hayasaka, A. Saito, S. Ogata
Journal: Journal of Thoracic Oncology (2018)
LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT+abiraterone acetate and prednisone (AAP) or placebo (PBO)
Authors: N. Matsubara, K.N. Chi, M. Ozguroglu, A. Rodriguez Antolin, S. Feyerabend, L. Fein, B.Y. Alekseev, G. Sulur, A. Protheroe, S. Li, S.D. Mundle, P. De Porre, N. Tran, K. Fazazi
Journal: Annals of Oncology (2018)
UK campaigners call for legislative shake up to tackle “dirty air crisis”
Authors: Zosia Kmietowicz
Journal: BMJ (2018)

Health campaigners are calling for a raft of legally enforceable standards to deal with the UK’s “dirty air crisis.”

An independent statutory body should be established to ensure that these standards are consistently implemented to achieve cleaner air across the country, says the UK Health Alliance on Climate Change, a coalition of health organisations and professionals advocating for action on climate change to protect public health.

The alliance would also like to see a group set up to advise the government on air pollution in much the same way as the Committee on Climate Change does on climate …
Programmed cell death ligand 1 expression and CD8 positive lymphocytes in stage III non-small cell lung cancer after neo adjuvant concurrent chemoradiotherapy and their relation with prognosis
Authors: E. Choe, C. Yoon-Jin, H.-S. Shim, C.-Y. Lee, B.C. Cho, H.-R. Kim
Journal: Annals of Oncology (2018)
End the culture of fear in healthcare
Authors: Navjoyt Ladher
Journal: BMJ (2018)

A key finding of the independent report into deaths at Gosport War Memorial Hospital, where around 600 people received fatal and medically unjustified doses of opioids, was a hospital culture of uncritical deference to doctors and a fear of raising concerns. In an essay this week Philip Darbyshire and David Thompson issue an urgent call for the report to serve as a tipping point in ending professional hierarchies in clinical practice (doi:10.1136/bmj.k4270). Subservience and …
A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial
Authors: S. Peters, S.J. Danson, B. Hasan, N. Reinmuth, M. Majem, K.G. Tournoy, M.T. Mark, M. Pless, M. Cobo, D. Rodriguez-Abreu, L. Falchero, B. Massutí, L. Coate, R. von Moos, C.C. Zielinski, E. De Maio, M. O’Brien, H. Roschitzki-Voser, U. Dafni, R.A. Stahel
Journal: Annals of Oncology (2018)
MA23.11 Lobe-Specific Nodal Dissection for Clinical Stage I and II Non-Small Cell Lung Cancer: Japanese Multi-Institutional Retrospective Study
Authors: T. Hishida, E. Miyaoka, K. Yokoi, H. Asamura, K. Kiura, K. Takahashi, H. Dosaka-Akita, H. Kobayashi, H. Date, H. Tada, M. Okumura, I. Yoshino
Journal: Journal of Thoracic Oncology (2018)
Safety of belotecan as second-line treatment for recurrent small cell lung cancer: A phase IIb randomized multicenter study
Authors: J.H. Kang, H.T. Kim, K.H. Lee, D.-W. Kim, S.-W. Kim, H.R. Kim, J.-H. Kim, J.H. Choi, H.J. An, J.-S. Kim, J.S. Jang, B.-S. Kim
Journal: Annals of Oncology (2018)
Geriatric oncology (GO): Long term follow-up of a prospective series of the GO unit at A.C. Camargo Cancer Center
Authors: A.L.A. Dettino, M.D.S. Donadio, A. Cabral, V.H.F.D. Jesus, M.F. Fanelli, S.M. Sanches
Journal: Annals of Oncology (2018)
Lymphogranuloma venereum (LGV) in men who have sex with men (MSM): a re-emerging problem, Malta, 2018
Authors: Alastair Donachie, Gianfranco Spiteri, Christopher Barbara, Tanya Melillo, Ronza Hadad, Alexandra Gauci Farrugia, Magnus Unemo, Valeska Padovese
Journal: Eurosurveillance (2018)

From 1 January to 30 June 2018, 11 cases of Lymphogranuloma venereum (LGV; all preserved samples (n = 4) genovar L2b) were identified at the Genitourinary Clinic (GUC), Mater Dei Hospital, Msida, Malta. All cases were diagnosed in men who have sex with men (MSM); six participated in three group-sex parties. Here, we describe the outbreak and risk factors associated with LGV diagnoses in MSM in Malta in 2018.
Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
Authors: S.T. Tagawa, S. Vallabhajosula, Y. Jhanwar, A. Hackett, C. Oromendia, M.J. Naiz, S.J. Goldsmith, D.M. Nanus, H. Beltran, A.M. Molina, B. Faltas, J. Sreekumar, J. Babich, K. Ballman, N.H. Bander
Journal: Annals of Oncology (2018)
MA11.05 Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact
Authors: F. Agustoni, H. Yu, K. Ellison, D. Smith, P. Mitchell, G. Rivalland, R. Dziadziuszko, D. Gao, K. Suda, S. Ren, C. Rivard, C. Caldwell, L. Rozeboom, K. Brovsky, D. Cortinovis, P. Bidoli, F. Hirsch
Journal: Journal of Thoracic Oncology (2018)
P1.17-08 Genetic Predictors of Response to Chemoradiation in Stage III Non-Small-Cell Lung Cancer
Authors: L. Luo, R. Samstein, R. Dick-Godfrey, B. Sidiqi, C. Wang, F. Oro, M. Sonnick, P. Paik, J. Chaft, A. Rimner, A. Wu
Journal: Journal of Thoracic Oncology (2018)
Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study
Authors: I. Bondarenko, O. Juan-Vidal, G. Pajkos, A. Kryzhanivska, Z. Pápai Székely, D. Vicente, I.O. Vynnychenko, S. Jones, Y. Wang, H. Jiang, N. Reinmuth
Journal: Annals of Oncology (2018)
MA24.03 Biologic Profiling of Pre-Metastatic Niche in Completely Resected Pathological Stage I Non-Small Cell Lung Cancer
Authors: T. Saito, H. Ryota, M. Ishida, K. Fukumoto, H. Matsui, Y. Taniguchi, H. Yanagimoto, K. Tsuta, T. Murakawa
Journal: Journal of Thoracic Oncology (2018)
IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma
Authors: Giulia Biffi, Tobiloba E. Oni, Benjamin Spielman, Yuan Hao, Ela Elyada, Youngkyu Park, Jonathan Preall, David A. Tuveson
Journal: Cancer Discovery (2018)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is poorly responsive to therapies and histologically contains a paucity of neoplastic cells embedded within a dense desmoplastic stroma. Within the stroma, cancer-associated fibroblasts (CAF) secrete tropic factors and extracellular matrix components, and have been implicated in PDAC progression and chemotherapy resistance. We recently identified two distinct CAF subtypes characterized by either myofibroblastic or inflammatory phenotypes; however, the mechanisms underlying their diversity and their roles in PDAC remain unknown. Here, we use organoid and mouse models to identify TGFβ and IL1 as tumor-secreted ligands that promote CAF heterogeneity. We show that IL1 induces LIF expression and downstream JAK/STAT activation to generate inflammatory CAFs and demonstrate that TGFβ antagonizes this process by downregulating IL1R1 expression and promoting differentiation into myofibroblasts. Our results provide a mechanism through which distinct fibroblast niches are established in the PDAC microenvironment and illuminate strategies to selectively target CAFs that support tumor growth. Significance: Understanding the mechanisms that determine CAF heterogeneity in PDAC is a prerequisite for the rational development of approaches that selectively target tumor-promoting CAFs. Here, we identify an IL1-induced signaling cascade that leads to JAK/STAT activation and promotes an inflammatory CAF state, suggesting multiple strategies to target these cells in vivo. See related commentary by Ling and Chiao, p. 173. This article is highlighted in the In This Issue feature, p. 151
OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study
Authors: L. Mezquita, F. Barlesi, E. Auclin, D. Planchard, A. Botticella, A. Gazzah, P. Lavaud, F. Aboubakar Nana, C. Lepéchoux, B. Besse
Journal: Journal of Thoracic Oncology (2018)
P1.05-04 Cone-Beam CT Confirms the Status of Transbronchial Biopsy Under Virtual Bronchoscopic Navigation for Peripheral Lung Lesions
Authors: N. Kawakita, H. Takizawa, E. Ali, M. Takashima, D. Matsumoto, T. Sawada, M. Tsuboi, H. Toba, M. Yoshida, Y. Kawakami, K. Kondo, A. Tangoku
Journal: Journal of Thoracic Oncology (2018)
Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data
Authors: T.K. Owonikoko, K.P. Papadopoulos, M. Gil-Martin, V. Moreno, A.K. Salama, E. Calvo, H. Safran, A. González-Martín, R. Aljumaily, D. Mahadevan, J. Niu, K. Kal Mohan, J. Li, E. Stankevich, M. Mathias, I. Lowy, M.G. Fury, H.M. Babiker
Journal: Annals of Oncology (2018)
Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma
Authors: Sarah M. Cheal, Hong Xu, Hong-fen Guo, Mitesh Patel, Blesida Punzalan, Edward K. Fung, Sang-gyu Lee, Meghan Bell, Manisha Singh, Achim A. Jungbluth, Pat B. Zanzonico, Alessandra Piersigilli, Steven M. Larson, Nai-Kong V. Cheung
Journal: Theranostics (2018)

In recent reports, we have shown that optimized pretargeted radioimmunotherapy (PRIT) based on molecularly engineered antibody conjugates and 177 Lu-DOTA chelate (DOTA-PRIT) can be used to cure mice bearing human solid tumor xenografts using antitumor antibodies to minimally internalizing membrane antigens, GPA33 (colon) and GD2 (neuroblastoma).However, many solid tumor membrane antigens are internalized after antibody binding and it is generally believed that internalizing tumor membrane antigens are not suitable targets for PRIT.In this study, we tested the hypothesis that DOTA-PRIT can be performed successfully to target HER2, an internalizing membrane antigen widely expressed in breast, ovarian, and gastroesophageal junction cancers.Methods: DOTA-PRIT was carried out in athymic nude mice bearing BT-474 xenografts, a HER2-expressing human breast cancer, using a three-step dosing regimen consisting of sequential intravenous administrations of: 1) a bispecific IgG-scFv (210 kD) format (BsAb) carrying the IgG sequence of the anti-HER2 antibody trastuzumab and the scFv "C825" with high-affinity, hapten-binding antibody for Bn-DOTA (metal) (BsAb: anti-HER2-C825), 2) a 500 kD dextran-based clearing agent, followed by 3) 177 Lu-DOTA-Bn.At the time of treatment, athymic nude mice bearing established subcutaneous BT-474 tumors (medium-and smaller-sized tumors with tumor volumes of 209 ± 101 mm 3 and ranging from palpable to 30 mm 3 , respectively), were studied along with controls.We studied single-and multi-dose regimens.For groups receiving fractionated treatment, we verified quantitative tumor targeting during each treatment cycle using non-invasive imaging with single-photon emission computed tomography/computed tomography (SPECT/CT).Results: We achieved high therapeutic indices (TI, the ratio of radiation-absorbed dose in tumor to radiation-absorbed dose to critical organs, such as bone marrow) for targeting in blood (TI = 28) and kidney (TI = 7), while delivering average radiation-absorbed doses of 39.9 cGy/MBq to tumor.Based on dosimetry estimates, we implemented a curative fractionated therapeutic regimen for medium-sized tumors that would deliver approximately 70 Gy to tumors, which required treatment with a total of 167 MBq 177 Lu-DOTA-Bn/mouse (estimated absorbed tumor dose: 66 Gy).This regimen was well tolerated and achieved 100% complete responses (CRs; defined herein as tumor volume equal to or smaller than 4.2 mm 3 ), including 62.5% histologic cure (5/8) and 37.5% microscopic residual disease (3/8) at 85 days (d).Treatment controls showed tumor progression to 207 ± 201% of pre-treatment volume at 85 d and no CRs.Finally, we show that treatment Ivyspring International
Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results
Authors: M. Gross-Goupil, T.G. Kwon, M. Eto, D. Ye, H. Miyake, S.I. Seo, S.S. Byun, J.L. Lee, V. Master, J. Jin, R. Debenedetto, R. Linke, M. Casey, B. Rosbrook, M.J. Lechuga Frean, O. Valota, E. Grande, D.I. Quinn
Journal: Annals of Oncology (2018)
Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?
Authors: S. Nagasawa, T. Ogata, K. Hara, Y. Shimoda, M. Nakazono, Y. Kumazu, T. Hayashi, T. Yamada, Y. Rino, M. Masuda, T. Yoshikawa, T. Oshima
Journal: Annals of Oncology (2018)
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
Authors: T. Macarulla Mercade, G. Bodoky, J. Siveke, K.-H. Lee, J. Chen, B. Mirakhur, A. Dean, L.-T. Chen, F. de Jong
Journal: Annals of Oncology (2018)
P1.05-12 18F-FDG PET/CT Findings May Predict Postoperative Acute Exacerbation of Interstitial Pneumonia in Lung Cancer Patients
Authors: H. Oishi, A. Sakurada, F. Hoshi, S. Eba, Y. Matsuda, T. Sado, M. Noda, Y. Okada
Journal: Journal of Thoracic Oncology (2018)
Rapid identification of bloodstream infection pathogens
Authors: N.I. Panova, O.I. Kit, O.Y. Kutsevalova, I.B. Lysenko, V.V. Dmitrieva, D.A. Rozenko, Y.A. Gevorkyan, E.E. Pak, O.V. Kozyuk, E.A. Kapuza, O.N. Shatokhina, N.V. Nikolaeva, E.A. Kalabanova, I.S. Mitashok, L.Y. Vladimirova
Journal: Annals of Oncology (2018)
P3.13-16 Concomitant EML4-ALK Rearrangement and EGFR Mutation in Non-Small Cell Lung Cancer Patients: Data from Eastern Indian Hospital.
Authors: P. Mohapatra, S. Bhuniya, M. Panigrahi, S. Patra, P. Mishra, S. Purkait, S. Dasmajumdar, S. Mohakud, S. Naik, S. Sahoo, S. Jagaty, S. Mohankudo, Y. Dhanurdhar, S. Panigrahi, M. Rahman, D. Muduly
Journal: Journal of Thoracic Oncology (2018)
P1.13-30 Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor and its Relationship to NSCLC Patient Outcomes in the REVEL Trial
Authors: E. Garon, A. Tsao, M. Reck, B. Levy, C. Visseren-Grul, H. Mao, A. Sashegyi, A. Chaudhry
Journal: Journal of Thoracic Oncology (2018)